Refine
Has Fulltext
- yes (128)
Is part of the Bibliography
- yes (128)
Year of publication
Document Type
- Journal article (71)
- Doctoral Thesis (56)
- Other (1)
Keywords
- ADHD (16)
- ADHS (12)
- children (10)
- Aufmerksamkeitsdefizit-Syndrom (6)
- adolescents (6)
- methylphenidate (6)
- Anorexia nervosa (5)
- Methylphenidat (5)
- therapeutic drug monitoring (5)
- Kind (4)
- Kinder- und Jugendpsychiatrie (4)
- adolescence (4)
- brain (4)
- eating disorders (4)
- fear generalization (4)
- Angst (3)
- Children (3)
- Furchtgeneralisierung (3)
- Jugend (3)
- Kinder (3)
- Kinder und Jugendliche (3)
- Komorbidität (3)
- NSSI (3)
- RCT (3)
- Schizophrenie (3)
- Serotonin (3)
- Substantia nigra (3)
- anorexia nervosa (3)
- brain development (3)
- mental health (3)
- pharmacovigilance (3)
- Angsterkrankungen (2)
- Angststörung (2)
- Arzneimittelüberwachung (2)
- Aufmerksamkeits-Defizit-Syndrom (2)
- Aufmerksamkeitsprozesse (2)
- Autismus-Spektrum-Störung (2)
- Brain-derived neurotrophic factor (2)
- COMT (2)
- Comorbidity (2)
- EEG (2)
- Early-onset (2)
- Elektroencephalogramm (2)
- Familienuntersuchung (2)
- Family-Investigation (2)
- Furcht (2)
- Furchtkonditionierung (2)
- GAD1 (2)
- Jugendliche (2)
- Kinderpsychiatrie (2)
- Komorbiditäten (2)
- OCD (2)
- PARK2 (2)
- Parkinson’s disease (2)
- Patientenzufriedenheit (2)
- Pharmakotherapie (2)
- Prävention (2)
- Psychische Störung (2)
- Qualitätssicherung (2)
- Satisfaction (2)
- TCS (2)
- Therapeutisches Drug Monitoring (2)
- Tourette syndrome (2)
- Transkranielle Sonographie (2)
- Transkranieller Ultraschall (2)
- Ultraschalldiagnostik (2)
- Zwangsstörung (2)
- anxiety disorders (2)
- attention deficit/hyperactivity disorder (2)
- attention-deficit/hyperactivity disorder (ADHD) (2)
- autism spectrum disorder (2)
- biomarkers (2)
- brain derived neurotrophic factor (2)
- brain disorders (2)
- case report (2)
- coercive measures (2)
- comorbidity (2)
- development (2)
- dopamine (2)
- dyslexia (2)
- emotion regulation (2)
- employee stress (2)
- event-related potentials (2)
- fMRI (2)
- fear conditioning (2)
- hiPSC (2)
- longitudinal study (2)
- nervous system (2)
- norepinephrine (2)
- outcome (2)
- paediatrics (2)
- parents (2)
- prosocial behavior (2)
- proteomics (2)
- psychiatric disorders (2)
- quality assurance (2)
- residential institutions (2)
- serum concentration (2)
- substantia nigra pars compacta (2)
- working memory (2)
- 1p36 deletion syndrome (1)
- 21q22.2-q22.3 (1)
- 22q11 (1)
- 22q11.2 deletion syndrome (1)
- 22q11.2- Deletionssyndrom (1)
- 5-HTTLPR (1)
- ADHDS (1)
- AKI (1)
- Adolescence (1)
- Adoleszenz (1)
- Altersunterschied (1)
- Amphetamin (1)
- Angst als Eigenschaft (1)
- Angstintensität (1)
- Angstsensitivität (1)
- Angststörungen (1)
- Animal model (1)
- Anorexia nervosa in childhood (1)
- Anorexia nervosa treatment satisfaction (1)
- Antwortinhibition (1)
- Anxiety (1)
- Arbeitsbelastung (1)
- Assoziationsstudie (1)
- Attention-deficit hyperactivity disorder (1)
- Attention-deficit/hyperactivity disorder (1)
- Attentional Avoidance (1)
- Attentional Bias (1)
- Attentional bias (1)
- Aufklärung (1)
- Aufklärungsgespräch (1)
- Aufmerksamkeitsdefitit-/ Hyperaktivitätsstörung (1)
- Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (1)
- Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (1)
- Aversive tension (1)
- BDNF (1)
- BMI (1)
- Behandlung (1)
- Behandlungszufriedenheit kindlicher Patienten mit Anorexia nervosa nach stationärem Klinikaufenthalt (1)
- Belastung Eltern (1)
- Benennungsgeschwindigkeit (1)
- Big Five (1)
- Biomarker (1)
- Biomarkers (1)
- Blutspiegel (1)
- Body Image Disturbance (1)
- Braak (1)
- Bruxismus (1)
- CDH13 (1)
- CNS imaging (1)
- CNV (1)
- CNVs (1)
- COVID-19 (1)
- CPT (1)
- Central nervous system (1)
- Child (1)
- Childhood (1)
- Clinical Genetics (1)
- Clozapin (1)
- Clozapin/clozapine (1)
- Cognitive Behavioral Analysis System of Psychotherapy (1)
- Comorbidity survey replication (1)
- Connexin (1)
- Continous performance test (1)
- Continous-Performance-Test (1)
- Continuous Performance Test (1)
- Conversion (1)
- D5 (DRD4, DRD5) (1)
- DBT (1)
- DS 22q11.2 (1)
- DSM-IV Subtyp (1)
- DSM-IV Subtype (1)
- DSM-IV disorders (1)
- De-novo (1)
- Deletionssyndrom (1)
- Depression (1)
- DiGeorge-Syndrom (1)
- Discrimination (1)
- Disease progression (1)
- Disease-modifying therapies (1)
- Diskrimination (1)
- Dissociation (1)
- Dissoziation (1)
- Distress (1)
- Dopamin Agonist (1)
- Dopamine (1)
- Drug development (1)
- Dyslexia (1)
- EPMS (1)
- ERP (1)
- ESCAlife (1)
- Eating Disorders (1)
- Eating disorder (1)
- Ecological momentary assessment (1)
- Eisen (1)
- Elterliche Stressbelastung (1)
- Eltern ADHS (1)
- Elterntraining (1)
- Emotion regulation (1)
- Enrichment analysis (1)
- Entwicklung (1)
- Ereigniskorrelierte Potentiale (1)
- Erratum (1)
- Essstörungen (1)
- Estrogene (1)
- Extrapyramidales System (1)
- Eßstörungen (1)
- FIQ (1)
- FOXP2 (1)
- Fear (1)
- Fear generalization (1)
- Fgf-signalling (1)
- Fibromyalgia (1)
- Follow-up (1)
- Fragebogen (1)
- Furchtentwicklung (1)
- GABA (1)
- GFAP (1)
- GRM8 (1)
- GWAS (1)
- Gedächtnis (1)
- Gedächtnisspanne (1)
- Gehirn (1)
- Geistige Behinderung (1)
- Genetic etiology (1)
- Genpolymophismen (1)
- Geruchsdiskrimination (1)
- Geruchsidentifikation (1)
- Geruchsschwelle (1)
- Geruchssinn (1)
- Geschlechter (1)
- Gesundheitsbeeinträchtigung (1)
- Gewalt (1)
- Guanfacin (1)
- Heimeinrichtungen (1)
- Herzfrequenzvariabilität (1)
- Hurst Exponent (1)
- Hyperactivity (1)
- Hypothalamus (1)
- Hysteria (1)
- Hysterie (1)
- Immunsuppression (1)
- Impulsivität (1)
- Informed consent (1)
- Internalisierende Störung (1)
- Interview (1)
- Jugendpsychiatrie (1)
- Juvenile Psychose (1)
- K-SADS (1)
- KDIGO (1)
- Kinder und Jugendliche/children and adolescents (1)
- Kinderschutz (1)
- Kindesalter (1)
- Kindheit und Jugend (1)
- Kleinkern (1)
- Klinisches Experiment (1)
- Knochendichte (1)
- Knochendichteverlauf (1)
- Konditionierung (1)
- Konversion (1)
- Körperschemastörung (1)
- LRS (1)
- Lebenslauf (1)
- Lese-Rechtschreibschwäche (1)
- Locomotor activity (1)
- Längsschnittstudie (1)
- Längsschnittuntersuchung (1)
- Medical students (1)
- Medicine (1)
- Medikation (1)
- Medizinisches Aufklärungsgespräch (1)
- Metaanalyse (1)
- Metaanalysis (1)
- Mikrodeletionssyndrom (1)
- Mikrodeletionssyndrom 22q11 (1)
- Mindfulness (1)
- Missbrauch (1)
- Mitarbeiterbelastung (1)
- Motorische Fertigkeiten (1)
- Motorische Fähigkeit (1)
- Mutationsanalyse (1)
- NGA (1)
- Neuromelanin (1)
- Neuropeptid Y (1)
- Neuroprotection (1)
- Nierentransplantion (1)
- Olanzapin (1)
- Olanzapin/olanzapine (1)
- Olfaction (1)
- Oral Fluid (1)
- Parent–Child Interaction Therapy (PCIT) (1)
- Parkinson (1)
- Parkinson's disease (1)
- Parkinson-Krankheit (1)
- Peripheral expression (1)
- Periphere Expression (1)
- Pharmakovigilanz (1)
- Prevalence (1)
- Psychiatrischer Notfall (1)
- Psychopharmakotherapie (1)
- Riechen (1)
- Risperidon (1)
- Ropinirol (1)
- SNP (1)
- STBS (1)
- Scale (1)
- Schlafbruxismus (1)
- Sekundärkrankheit (1)
- Serotonerges System (1)
- Smartphones (1)
- Speichel (1)
- Stimulanz (1)
- Stimulanzien (1)
- Stress (1)
- Stress prevention (1)
- Störung des Sozialverhaltens (1)
- Substantia Nigra - Echogenität (1)
- Subtypen (1)
- Suchrate (1)
- Surrogate endpoints (1)
- TDM (1)
- TIC disorder (1)
- TIC disorders (1)
- Therapeutic Drug Monitoring (1)
- Therapeutisches Drug Monitoring/therapeutic drug monitoring (1)
- Therapy (1)
- Therpeutisches Drug Monitoring (1)
- Thigmotaxis (1)
- Transplantation (1)
- Transplantatüberleben (1)
- Trios (1)
- Tyrosinkinase (1)
- Tyrosinkinase Connexin (1)
- VAL66MET polymorphism (1)
- VBM (1)
- VIGALL (1)
- Verhaltensauffälligkeiten (1)
- Verhaltensstörung (1)
- Verhaltenstherapie (1)
- Vigilanz (1)
- Waiting Impulsivity (1)
- Zebrafish (1)
- Zufriedenheit (1)
- Zwangsstörungen (1)
- Zweikomponentensystem <Molekularbiologie> (1)
- actigraphy (1)
- adhd (1)
- adolescence anorexia nervosa (1)
- adult attention deficit/hyperactivity disorder (1)
- adult development (1)
- adult neurogenesis (1)
- adult treatment (1)
- adverse drug reactions (1)
- adverse effects (1)
- adversity (1)
- affective disorders (1)
- agreeableness (1)
- allostatic load (1)
- amenorrhea (1)
- analgesic medication (1)
- anticipatory mechanisms (1)
- anxiety (1)
- anxiety intensity (1)
- anxiety sensitivity (1)
- artifacts (1)
- association (1)
- association study (1)
- atention deficit order (1)
- attention deficit hyperactivity disorder (1)
- attention deficit hyperactivity disorder (ADHD) (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- attention-deficit/hyperactivity disorder (1)
- attentional processes (1)
- auditory discrimination (1)
- autism (1)
- autism spectrum disorder (ASD) (1)
- autoantibodies (1)
- basal ganglia (1)
- behavior problems (1)
- behaviour problems (1)
- behaviour therapy (1)
- berufliche Einschränkungen (1)
- biomarker (1)
- bipolar disorder (1)
- body mass index (1)
- bone density (1)
- bone-mineral density (1)
- breastfeeding (1)
- cancer (1)
- cardiac surgery (1)
- catecholamines (1)
- caudate nucleus (1)
- challenging behavior (1)
- challenging behaviours (1)
- changes in bone density (1)
- child and adolescent (1)
- child and adolescent psychiatry (1)
- child behavior (1)
- child memory (1)
- childhood maltreatment (1)
- children/adults (1)
- chromosome 21 (1)
- chronotype (1)
- classical conditioning (1)
- classification (1)
- clinical characteristics (1)
- clinical study (1)
- clinical trial (1)
- common SNPS (1)
- comparative genomics (1)
- complex diseases (1)
- computational modeling (1)
- congenital heart-deffects (1)
- contingent negative-variation (1)
- continuous performance task (CPT) (1)
- continuous performance test (1)
- continuous performance-test (1)
- coping strategies (1)
- copy-number variation (1)
- correlate (1)
- cytogenetic effects (1)
- data quality (1)
- deficit hyperactivity disorder (1)
- deficit-hyperactivity disorder (1)
- deletionsyndrom (1)
- dementia with Lewy bodies (1)
- dental development in children (1)
- depression (1)
- depressive symptoms (1)
- depressiveness (1)
- developmental disabilities (1)
- developmental dyscalculia (1)
- developmental dyslexia (1)
- digital phenotyping (1)
- disability (1)
- discrimination training (1)
- disease modelling (1)
- disease progression (1)
- disease-modifying therapies (1)
- disorders (1)
- distal deletion (1)
- dopamine agonist (1)
- dopamine receptor D4 (1)
- dopamine transporter (DAT) (1)
- dopaminergics (1)
- doublecortine-like (1)
- drug development (1)
- drug safety (1)
- dual guidance (1)
- dyscalculia (1)
- early-onset (1)
- ecological momentary assessment (1)
- efficacy (1)
- electroencephalography (1)
- electroencephalography (EEG) (1)
- emotional dysregulation (1)
- emotional paradigm (1)
- emotionales Paradigma (1)
- endophenotype (1)
- ereigniskorrelierte Potentiale (1)
- excitatory/inhibitory imbalance (1)
- executive functions (1)
- expression (1)
- family (1)
- family relations (1)
- fear extinction (1)
- fear-relevant training (1)
- feedback (1)
- fibromyalgia syndrome (1)
- freiheitsentziehende Maßnahmen (1)
- frontal cortex (1)
- functional magnetic resonance imaging (1)
- gender (1)
- genes (1)
- genome-wide association (1)
- genomic imaging (1)
- gilles (1)
- girls (1)
- glucose transporter (1)
- guidelines & recommendations (1)
- haplotypes (1)
- health status (1)
- herausforderndes Verhalten (1)
- hierarchical modeling (1)
- hippocampus (1)
- iPSC (1)
- identification (1)
- immunosuppression (1)
- impulse control disorders (1)
- inattention/hyperactivity (1)
- inattentive (1)
- increases (1)
- individual workload (1)
- individualised modular treatment programme (1)
- intellectual disabilities (1)
- intellectual disability (1)
- intelligence (1)
- intra-individual variability (IIV) (1)
- inventory (1)
- kinase (1)
- kindliche Zahnentwicklung (1)
- klinische Studie (1)
- longitudinal studies (1)
- mRNA expression (1)
- maternal stress (1)
- mathematics (1)
- maturation (1)
- medication (1)
- melatonin (1)
- memory (1)
- memory-span (1)
- menarche (1)
- menstrual recovery (1)
- mental disorders (1)
- meta-analysis (1)
- metabotropic glutamate (mGlu) receptor (1)
- micronucleus assay (1)
- mindfulness (1)
- minimum reporting standards (1)
- mismatch (1)
- mismatch negativity mmn (1)
- missing heritability (1)
- mitochondria (1)
- mitochondrial pathology (1)
- mitochondrial translation (1)
- mobile crowdsensing (1)
- mobile health (1)
- molecular neuroscience (1)
- moral balancing (1)
- mothers (1)
- motor preparation (1)
- multicenter study (1)
- multi‑center cohort study (1)
- mutagenicity (1)
- naming-speed (1)
- nephrotransplantation (1)
- neurodegeneration (1)
- neurodevelopment (1)
- neurogenesis (1)
- neuromelanin granules (1)
- neuroprotection (1)
- neuropsychiatric disorders (1)
- nonsuicidal self-injury (NSSI) (1)
- noradrenaline (1)
- novelty detection (1)
- nucleus accumbens (1)
- objective assessment (1)
- obsessive-compulsive disorder (1)
- ocd (1)
- off label use (1)
- older adults (1)
- olfactory bulb neurogenesis (1)
- oppositional defiant disorder (1)
- oppositional-defiant disorder (1)
- ovarian function (1)
- parent training (1)
- parent-child interaction therapy (PCIT) (1)
- parent-child relationship (1)
- parental perception (1)
- parental stress (1)
- patient satisfaction (1)
- periodische Katatonie (1)
- peripheral expression (1)
- peripheral nerve involvement (1)
- periphere Expression Brain-derived neurotrophic factor (1)
- pharmacokinetics (1)
- pharmacotherapy (1)
- precursor symptoms (1)
- prelevance (1)
- preterm children (1)
- prevalence (1)
- prevention (1)
- probabilistic reversal learning (1)
- probiotic prophylaxis (1)
- processing deficits (1)
- prosocial (1)
- prosociality (1)
- protective factors (1)
- psychiatric comorbidity (1)
- psychiatric emergencies (1)
- psychische Belastung (1)
- psychological distress (1)
- psychopathology (1)
- psychopharmacotherapy (1)
- psychosis (1)
- psychotropic drugs (1)
- quantitative trait (1)
- rare diseases (1)
- reaction time (1)
- reading disability (1)
- recovery (1)
- reinforcement learning (1)
- reliability (1)
- renal (1)
- research errors (1)
- resilience (1)
- response-inhibition (1)
- responsivity (1)
- resumption of menses (1)
- return (1)
- review (1)
- risperidone (1)
- ropinirole (1)
- satisfaction with life (1)
- schizophrenia (1)
- schizophrenie (1)
- school (1)
- school-based prevention (1)
- schoolchildren (1)
- search-rate (1)
- selective mutism (1)
- self-injury (1)
- self-regulation (1)
- selfcompassion (1)
- serotonin (1)
- short-term methylphenidate brain (1)
- single photon emission computed tomography (SPECT) (1)
- skin conductance (1)
- sleep (1)
- sleep bruxism (1)
- slow cortical potentials (1)
- social influence (1)
- social recognition (1)
- speech perception (1)
- stem cells (1)
- stimulant (1)
- strength and difficulties (1)
- stress (1)
- stress granules (1)
- stress reduction (1)
- stressful life events (1)
- striatum (1)
- study (1)
- subtypes (1)
- subventricular zone (1)
- suicidality (1)
- sulcal morphology (1)
- supplements (1)
- support vector machines (1)
- surrogate endpoints (1)
- susceptibility gene (1)
- synaptosomes (1)
- syndrome (1)
- target weight (1)
- telephone-assisted self-help (1)
- tetrahydroisoquinoline derivates (1)
- third-wave psychotherapy (1)
- tiapride (1)
- tic disorders (1)
- tics (1)
- transcranial sonography (1)
- transcutaneous auricular vagus nerve stimulation (1)
- transcutaneous cervical vagus nerve stimulation (1)
- transcutaneous vagus nerve stimulation (1)
- transplantation (1)
- transporter gene SLC2A3 (1)
- treatment (1)
- triads (1)
- tumor-suppressor gene (1)
- unerwünschte Arzneimittelwirkungen (1)
- universal prevention (1)
- ventricular zone (1)
- vitamin D (1)
- weight gain (1)
- Östrogene (1)
- Übergewicht (1)
Institute
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (128) (remove)
Sonstige beteiligte Institutionen
Emotional dysregulation and its pathways to suicidality in a community-based sample of adolescents
(2024)
Objective
Effective suicide prevention for adolescents is urgently needed but difficult, as suicide models lack a focus on age-specific influencing factors such as emotional dysregulation. Moreover, examined predictors often do not specifically consider the contribution to the severity of suicidality.
To determine which adolescents are at high risk of more severe suicidality, we examined the association between emotional dysregulation and severity of suicidality directly as well as indirectly via depressiveness and nonsuicidal self-injury.
Method
Adolescents from 18 high schools in Bavaria were included in this cross-sectional and questionnaire-based study as part of a larger prevention study. Data were collected between November 2021 and March 2022 and were analyzed from January 2023 to April 2023.
Students in the 6th or 7th grade of high school (11–14 years) were eligible to participate. A total of 2350 adolescents were surveyed and data from 2117 students were used for the analyses after excluding incomplete data sets. Our main outcome variable was severity of suicidality (Paykel Suicide Scale, PSS). Additionally, we assessed emotional dysregulation (Difficulties in Emotion Regulation Scale, DERS-SF), depressiveness (Patient Health Questionnaire, PHQ-9) and nonsuicidal self-injury (Deliberate Self-Harm Inventory, DSHI).
Results
In total, 2117 adolescents (51.6% female; mean age, 12.31 years [standard deviation: 0.67]) were included in the structural equation model (SEM). Due to a clear gender-specific influence, the model was calculated separately for male and female adolescents. For male adolescents, there was a significant indirect association between emotional dysregulation and severity of suicidality, mediated by depressiveness (β = 0.15, SE = .03, p = .008). For female adolescents, there was a significant direct path from emotional dysregulation to severity of suicidality and also indirect paths via depressiveness (β = 0.12, SE = .05, p = 0.02) and NSSI (β = 0.18, SE = .04, p < .001).
Conclusions
Our results suggest that gender-related risk markers in 11–14-year-olds need to be included in future suicide models to increase their predictive power. According to our findings, early detection and prevention interventions based on emotion regulation skills might be enhanced by including gender-specific adjustments for the co-occurrence of emotional dysregulation, depressiveness, and nonsuicidal self-injury in girls and the co-occurrence of emotional dysregulation and depressiveness in boys.
Human prosociality, encompassing generosity, cooperation, and volunteering, holds a vital role in our daily lives. Over the last decades, the question of whether prosociality undergoes changes over the adult lifespan has gained increased research attention. Earlier studies suggested increased prosociality in older compared to younger individuals. However, recent meta-analyses revealed that this age effect might be heterogeneous and modest. Moreover, the contributing factors and mechanisms behind these age-related variations remain to be identified. To unravel age-related differences in prosociality, the first study of this dissertation employed a meta-analytical approach to summarize existing findings and provide insight into their heterogeneity by exploring linear and quadratic age effects on self-reported and behavioral prosociality. Additionally, two empirical research studies investigated whether these age-related differences in prosociality were observed in real life, assessed through ecological momentary assessment (Study 2), and in a controlled laboratory setting by applying a modified dictator game (Study 3). Throughout these three studies, potential underlying behavioral and computational mechanisms were explored. The outcome of the meta-analysis (Study 1) revealed small linear age effects on prosociality and significant age group differences between younger and older adults, with higher levels of prosociality in older adults. Explorative evidence emerged in favor of a quadratic age effect on behavioral prosociality, indicating the highest levels in midlife. Additionally, heightened prosocial behavior among middle-aged adults was observed compared to younger adults, whereas no significant differences in prosocial behavior were noted between middle-aged and older adults. Situational and contextual features, such as the setting of the study and specific paradigm characteristics, moderated the age-prosociality relationship, highlighting the importance of the (social) context when studying prosociality. For Study 2, no significant age effect on real-life prosocial behavior was observed. However, evidence for a significant linear and quadratic age effect on experiencing empathy in real life emerged, indicating a midlife peak. Additionally, across all age groups, the link between an opportunity to empathize and age significantly predicted real-life prosocial behavior. This effect, indicating higher levels of prosocial behavior when there was a situation possibly evoking empathy, was most pronounced in midlife. Study 3 presented age differences in how older and younger adults integrate values related to monetary gains for self and others to make a potential prosocial decision. Younger individuals effectively combined both values in a multiplicative fashion, enhancing decision-making efficiency. Older adults showed an additive effect of values for self and other and displayed increased decision-making efficiency when considering the values separately. However, among older adults, individuals with better inhibitory control were better able to integrate information about both values in their decisions. Taken together, the findings of this dissertation offer new insights into the multi-faceted nature of prosociality across adulthood and the mechanisms that help explain these age-related disparities. While this dissertation observed increasing prosociality across the adult lifespan, it also questions the assumption that older adults are inherently more prosocial. The studies highlight midlife as a potential peak period in social development but also emphasize the importance of the (social) context and that different operationalizations might capture distinct facets of prosociality. This underpins the need for a comprehensive framework to understand age effects of prosociality better and guide potential interventions.
Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier.
Purpose
Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated.
Methods
Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures.
Results
In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs.
Conclusions
This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml).
Psychotropic drugs are frequently prescribed ‘off-label’ to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5%) received psychopharmacological treatment. In 53 (8.1%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results.
Risperidone is commonly used to treat different psychiatric disorders worldwide. Knowledge on dose–concentration relationships of risperidone treatment in children and adolescents with schizophrenia or other psychotic disorders is, however, scarce and no age-specific therapeutic ranges have been established yet. Multicenter data of a therapeutic drug monitoring service were analyzed to evaluate the relationship between risperidone dose and serum concentration of the active moiety (risperidone (RIS) plus its main metabolite 9-hydroxyrisperidone (9-OH-RIS)) in children and adolescents with psychotic disorders. Patient characteristics, doses, serum concentrations and therapeutic outcomes were assessed by standardized measures. The study also aimed to evaluate whether the therapeutic reference range for adults (20–60 ng/ml) is applicable for minors. In the 64 patients (aged 11–18 years) included, a positive correlation between daily dose and the active moiety (RIS\(_{am}\)) concentration was found (r\(_s\) = 0.49, p = 0.001) with variation in dose explaining 24% (r\(_s\)\(^2\) = 0.240) of the variability in serum concentrations. While the RIS\(_{am}\) concentration showed no difference, RIS as well 9-OH-RIS concentrations and the parent to metabolite ratio varied significantly in patients with co-medication of a CYP2D6 inhibitor. Patients with extrapyramidal symptoms (EPS) had on average higher RIS\(_{am}\) concentrations than patients without (p = 0.05). Considering EPS, the upper threshold of the therapeutic range of RIS\(_{am}\) was determined to be 33 ng/ml. A rough estimation method also indicated a possibly decreased lower limit of the preliminary therapeutic range in minors compared to adults. These preliminary data may contribute to the definition of a therapeutic window in children and adolescents with schizophrenic disorders treated with risperidone. TDM is recommended in this vulnerable population to prevent concentration-related adverse drug reactions.
Für Kinder und Jugendliche stellt die Blutentnahme im Rahmen des Therapeutischen Drug Monitorings (TDM) aufgrund der Invasivität häufig eine große physische sowie psychische Belastung dar. Diese Stresssituation kann durch Speichelsammlung aufgrund des nicht invasiven Prozederes vermieden und zusätzlich der Material-, Personal- und Zeitaufwand im Vergleich zu einer Blutentnahme minimiert werden. Da die therapeutischen Referenzbereiche in der AGNP Konsensus-Leitlinie zum TDM von Psychopharmaka nur für Serum und Plasma validiert sind, sind vergleichende Untersuchungen von alternativen Matrizes mit Serum oder Plasma sowie eine klinische Validierung essenziell für die Implementierung in die klinische Praxis.
Die Zielsetzung dieser Arbeit war es daher, den Zusammenhang zwischen Speichel- und Serumkonzentrationen von Amphetamin und Guanfacin zu untersuchen, um zukünftig das Prozedere der Probenahme für TDM bei Kinder und Jugendliche unter ADHS-Pharmakotherapie durch ein nicht invasives Verfahren zu erleichtern. Zur quantitativen Bestimmung wurden zwei unterschiedliche Methoden aus der Literatur weiterentwickelt. So war es möglich, aus Speichel- und Serumproben Amphetamin mittels HPLC-FL Analytik sowie Guanfacin mittels LC-MS/MS Analytik zu quantifizieren. Die chromatographischen Methoden wurden in Anlehnung an die Richtlinien der Gesellschaft für toxikologische und forensische Chemie (GTFCh) erfolgreich validiert.
Zur Untersuchung des Zusammenhangs zwischen Speichel- und Serumkonzentrationen von Amphetamin und Guanfacin bei Kinder und Jugendlichen wurde eine klinische Studie in der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie des Universitätsklinikum Würzburgs initiiert. Von 34 Probanden, die mit Lisdexamphetamin und/oder Guanfacin behandelt wurden, konnte jeweils eine korrespondierende Speichel- und Serumprobe gewonnen und quantifiziert werden. Für Amphetamin wurde belegt, dass der Speichel-pH-Wert einen erheblichen Einfluss auf die Wirkstoffverteilung, den Quotienten aus Speichel- und Serumkonzentration, hat (ρ = -0,712; P < 0,001). Dadurch konnte erstmalig unter Berücksichtigung des Speichel-pH-Wertes eine Berechnung der theoretischen Serumkonzentration aus der Speichelkonzentration durchgeführt werden. Es wurde zwar gezeigt, dass sich sowohl der Mittelwert der Differenzen durch die Berechnung theoretischen Serumkonzentration von -343 auf 12 ng/mL als auch die Anzahl der Messwert innerhalb des Akzeptanzintervalls von 20 % verbessern, jedoch war auch nach der Umrechnung die Differenz der Messwerte zu groß, sodass eine klinische Validierung für Amphetamin nicht möglich war. In dieser Studie wurde auch erstmals Guanfacin im Speichel nachgewiesen und quantifiziert, die Konzentrationen lagen zwischen 0,45 und 5,55 ng/mL und waren im Mittel dreifach niedriger als im Serum (2,36 ng/mL vs. 7,47 ng/mL; t (8) = 5,94; P < 0,001).
Die Speichelguanfacinkonzentration wies einen starken Zusammenhang mit der korrespondierenden Serumkonzentration auf (r = 0,758; P = 0,018). Obwohl ein nicht signifikanter Trend für den Einfluss des Speichel-pH-Wertes auf den Quotienten aus Speichel- und Serumkonzentration zu erkennen war, scheint dieser weniger stark ausgeprägt zu sein als bei Amphetamin und anderen basischen Arzneistoffen (r = -0,574; P = 0,106).
Mit der vorliegenden Arbeit konnte zum einen gezeigt werden, dass sich die Speichelbestimmung von Amphetamin nur zum qualitativen Nachweis für TDM eignet. Zum anderen konnte gezeigt werden, dass der Speichel-pH-Wert einen geringeren Einfluss auf die Speichelkonzentration von Guanfacin zu haben scheint, als es bei Amphetamin der Fall ist, und sich Guanfacin somit potenziell für TDM in Speichel eignet. Zukünftig könnten Speichelproben zur Kontrolle der Adhärenz sowohl von Amphetamin als auch von Guanfacin verwendet werden und die Probenahme für die Patienten vereinfachen.
Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) gehört weltweit zu den bedeutendsten psychiatrischen Erkrankungen des Kinder- und Jugendalters. Die Pathomechanismen sind aktuell noch nicht vollständig geklärt, wobei es deutliche Hinweise auf hirnorganische Veränderungen gibt. Die transkranielle Sonographie stellt eine nicht-invasive Methode dar, strukturelle Unterschiede tiefer Hirnstrukturen zu untersuchen. Bereits in vorangegangenen Studien konnte mit der Methode eine Veränderung der Echogenität der Substantia nigra (SN) bei Kindern mit ADHS im Vergleich zu gesunden Kontrollprobanden nachgewiesen werden. In dieser Studie sollen nun die möglichen physiologischen Hintergründe der erhöhten Echogenität der Substantia Nigra in Zusammenschau mit bildgebenden Verfahren betrachtet werden. Hierzu wurde in der vorliegenden multimodalen Studie bei 20 männlichen Kindern mit ADHS im Alter zwischen 8 und 12 Jahren eine transkranielle Ultraschalluntersuchung (TCS) zur Bestimmung der echogenen Fläche der Substantia Nigra sowie ein neuromelaninsensitives cMRT zur Bestimmung des neuromelaninassoziierten Volumens der SN, sowie des neuromelaninassoziierten Kontrastes SN/Cb durchgeführt. Als Kennwerte des peripheren Eisenhaushalts wurden die Konzentrationen von Eisen, Ferritin und Transferrin im Blut bestimmt. In die Auswertung gingen außerdem die Stärke der ADHS-Symptomatik (Strength and Difficulties Questionaire, SDQ; Fremdbeurteilungsbogen bei ADHS, FBB-ADHS), die kognitive Begabung (über CFT-20-R) und das Alter der Probanden ein. Psychiatrische Komorbidität wurde mit Hilfe der Child Behaviour Checklist (CBCL) erhoben.
Psychopathology, protective factors, and COVID-19 among adolescents: a structural equation model
(2023)
Since the outbreak of the COVID-19 pandemic in December 2019 and the associated restrictions, mental health in children and adolescents has been increasingly discussed in the media. Negative impacts of the pandemic, including a sharp increase in psychopathology and, consequently, reduced quality of life, appear to have particularly affected children and young people, who may be especially vulnerable to the adverse effects of isolation. Nevertheless, many children and adolescents have managed to cope well with the restrictions, without deterioration of their mental health. The present study therefore explored the links between COVID-19 infection (in oneself or a family member, as well as the death of a family member due to the virus), protective factors such as self-efficacy, resilience, self-esteem, and health-related quality of life, and measures of psychopathology such as depression scores, internalizing/externalizing problems, emotion dysregulation, and victimization. For this purpose, we examined data from 2129 adolescents (mean age = 12.31, SD = 0.67; 51% male; 6% born outside of Germany) using a structural equation model. We found medium to high loadings of the manifest variables with the latent variables (COVID-19, protective factors, and psychopathology). Protective factors showed a significant negative correlation with psychopathology. However, COVID-19 had a weak connection with psychopathology in our sample. External pandemic-related factors (e.g., restrictions) and their interaction with existing psychopathology or individual protective factors appear to have a greater influence on young people’s mental health than the impact of the virus per se. Sociopolitical efforts should be undertaken to foster prevention and promote individual resilience, especially in adolescence.